In late October 2019, FDA approved elexacaftor/tezacaftor/ivacaftor and ivacaftor (Trikafta—Vertex Pharmaceuticals), the first triple-combination therapy to treat patients ages 12 years and older with at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which is estimated to represent 90% of the cystic fibrosis (CF) population.

Cara Aldridge Young

The American Heart Association (AHA) and the American College of Cardiology (ACC) jointly released a set of performance and quality measures for adults with high blood pressure that closely align with AHA/ACC’s blood pressure guidelines published in late 2017.

Loren Bonner

All pharmacists know that for many conditions, medication isn’t enough. True management of chronic diseases takes a 360° approach that includes exercise, smoking cessation, and—unavoidably—nutrition.

Rachel Balick

Cough—a symptom of diverse infectious and noninfectious disorders that is classified as acute (<3 weeks), subacute (3–8 weeks), or chronic (>8 weeks)—is an important defensive respiratory reflex with potentially significant adverse physical and psychological consequences and economic impact.

Daniel L. Krinsky, RPh, MS

Updates from FDA